Ultragenyx Pharmaceu (RARE)

$20.42 -0.04 (-0.20%)
Market Cap 1.98B
Revenue (ttm) 673.00M
Net Income (ttm) -575.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -85.44%
Debt to Equity Ratio 0.00
Volume 1,654,000
Avg Vol 2,342,484
Day's Range N/A - N/A
Shares Out 96.63M
Stochastic %K 16%
Beta 0.16
Analysts Strong Sell
Price Target $54.25

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
PARA_85
PARA_85 Mar. 18 at 7:47 PM
$RARE in
0 · Reply
LongerThanLong
LongerThanLong Mar. 17 at 11:55 AM
$RARE check the Alzheimer results of the subsidiary Amlogenyx: https://www.biospace.com/press-releases/amlogenyx-announces-positive-preclinical-data-on-am805-a-potent-amyloid-degrading-protease-for-the-treatment-of-alzheimers-disease This is getting better and better
0 · Reply
11thestate
11thestate Mar. 17 at 11:30 AM
As we were exploring $RARE, we came across this. (And it’s the kind of thing you’re not prepared to see): https://11th.com/cases/ultragenyxpharmaceutical-investor-suit
1 · Reply
anachartanalyst
anachartanalyst Mar. 12 at 7:02 PM
$RARE https://anachart.com/wp-content/uploads/ana_temp/1773342119_soc-img.jpg
0 · Reply
mru01
mru01 Mar. 12 at 2:47 PM
$RARE why is it dropping after that positive news?
1 · Reply
mru01
mru01 Mar. 12 at 1:21 PM
$RARE positive Phase 3 data
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 11 at 9:18 PM
$SLS $SLS Every SLS investor is literally Guaranteed a Huge Return as the Share Price will continue to Climb while we wait for Imminent Phase 3 Results -Could be Announced ANY DAY NOW and are worth $40B / $180 Per Share to Big Pharma. The Share Price Will Continue Climbing until it absolutely launches. - Just a couple errors in this article re Valuation/ Cash $115M /The CASH, which had caused such an overhang on the Share Price - is NOW a Huge Catalyst $115M will be Reported in the 10K this week/next? and a TINY $6.2-$6.5M Burn... PLUS the KICKER SLS has nearly $400M on Deck. +700M when you add in Remaining Warrant CASH AND $RARE Priority Review Cash. Link to full article. Archive.phhttps://seekingalpha.com/article/4878989-sellas-regal-study-results-due-any-day-major-potential-upside-catalyst
0 · Reply
LoveRetailFroth
LoveRetailFroth Mar. 11 at 2:15 PM
$VIVO Good Morning ☕️ $RARE $TEMT $AMLX $DTIL
0 · Reply
Masonsy
Masonsy Mar. 10 at 7:09 PM
$RARE did the CMO mention the progress of UX111 BLA resubmission during the fireside chat on Barclays Conference earlier today? I heard ‘more to come’ shortly…
1 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 6:52 PM
$RARE Ultragenyx Pharmaceutical (NASDAQ: RARE) is gaining attention among investors searching for high-growth biotechnology stocks. With a pipeline focused on rare genetic diseases and strong analyst price targets, the biotech stock could deliver more than 160% upside. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-invest-in-ultragenyx-pharmaceutical-rare/
0 · Reply
Latest News on RARE
Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Mar 12, 2026, 1:35 PM EDT - 7 days ago

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Mar 12, 2026, 8:47 AM EDT - 7 days ago

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 11, 2026, 12:32 PM EDT - 8 days ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Leerink Global Healthcare Conference 2026 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 3:10 PM EDT - 9 days ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 4:47 PM EST - 17 days ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 24, 2026, 9:11 AM EST - 23 days ago

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Ultragenyx to Participate at Investor Conferences in March

Feb 23, 2026, 4:30 PM EST - 24 days ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Feb 23, 2026, 8:30 AM EST - 24 days ago

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 20, 2026, 4:30 PM EST - 27 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Feb 18, 2026, 2:07 PM EST - 4 weeks ago

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript

Feb 13, 2026, 6:47 PM EST - 4 weeks ago

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript

Why Is Ultragenyx Stock Sinking Friday?

Feb 13, 2026, 1:21 PM EST - 4 weeks ago

Why Is Ultragenyx Stock Sinking Friday?

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Feb 12, 2026, 4:01 PM EST - 5 weeks ago

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical

Feb 9, 2026, 4:30 PM EST - 5 weeks ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Feb 9, 2026, 3:01 AM EST - 5 weeks ago

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Feb 3, 2026, 8:00 AM EST - 6 weeks ago

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Jan 30, 2026, 8:30 AM EST - 6 weeks ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Jan 23, 2026, 2:05 PM EST - 7 weeks ago

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline

Jan 22, 2026, 6:01 AM EST - 2 months ago

Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline

Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:55 PM EST - 2 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 2 months ago

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Dec 30, 2025, 4:05 PM EST - 2 months ago

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Dec 30, 2025, 2:24 PM EST - 2 months ago

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

Dec 30, 2025, 9:52 AM EST - 2 months ago

Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dec 29, 2025, 1:05 PM EST - 2 months ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

MREO

Ultragenyx's bone disease drug fails late-stage trials

Dec 29, 2025, 8:35 AM EST - 2 months ago

Ultragenyx's bone disease drug fails late-stage trials

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Dec 29, 2025, 8:30 AM EST - 2 months ago

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

Dec 14, 2025, 11:30 PM EST - 3 months ago

AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings

ABBV ALGT CGNX COHR EOLS INSP LTH

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 3:23 PM EST - 3 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 3:13 AM EST - 3 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 12:26 AM EST - 4 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Nov 4, 2025, 4:01 PM EST - 4 months ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 4:30 PM EDT - 5 months ago

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Sep 30, 2025, 4:05 PM EDT - 6 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 10:13 AM EDT - 6 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 12:17 PM EDT - 6 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Sep 8, 2025, 4:05 PM EDT - 6 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

PARA_85
PARA_85 Mar. 18 at 7:47 PM
$RARE in
0 · Reply
LongerThanLong
LongerThanLong Mar. 17 at 11:55 AM
$RARE check the Alzheimer results of the subsidiary Amlogenyx: https://www.biospace.com/press-releases/amlogenyx-announces-positive-preclinical-data-on-am805-a-potent-amyloid-degrading-protease-for-the-treatment-of-alzheimers-disease This is getting better and better
0 · Reply
11thestate
11thestate Mar. 17 at 11:30 AM
As we were exploring $RARE, we came across this. (And it’s the kind of thing you’re not prepared to see): https://11th.com/cases/ultragenyxpharmaceutical-investor-suit
1 · Reply
anachartanalyst
anachartanalyst Mar. 12 at 7:02 PM
$RARE https://anachart.com/wp-content/uploads/ana_temp/1773342119_soc-img.jpg
0 · Reply
mru01
mru01 Mar. 12 at 2:47 PM
$RARE why is it dropping after that positive news?
1 · Reply
mru01
mru01 Mar. 12 at 1:21 PM
$RARE positive Phase 3 data
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 11 at 9:18 PM
$SLS $SLS Every SLS investor is literally Guaranteed a Huge Return as the Share Price will continue to Climb while we wait for Imminent Phase 3 Results -Could be Announced ANY DAY NOW and are worth $40B / $180 Per Share to Big Pharma. The Share Price Will Continue Climbing until it absolutely launches. - Just a couple errors in this article re Valuation/ Cash $115M /The CASH, which had caused such an overhang on the Share Price - is NOW a Huge Catalyst $115M will be Reported in the 10K this week/next? and a TINY $6.2-$6.5M Burn... PLUS the KICKER SLS has nearly $400M on Deck. +700M when you add in Remaining Warrant CASH AND $RARE Priority Review Cash. Link to full article. Archive.phhttps://seekingalpha.com/article/4878989-sellas-regal-study-results-due-any-day-major-potential-upside-catalyst
0 · Reply
LoveRetailFroth
LoveRetailFroth Mar. 11 at 2:15 PM
$VIVO Good Morning ☕️ $RARE $TEMT $AMLX $DTIL
0 · Reply
Masonsy
Masonsy Mar. 10 at 7:09 PM
$RARE did the CMO mention the progress of UX111 BLA resubmission during the fireside chat on Barclays Conference earlier today? I heard ‘more to come’ shortly…
1 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 6:52 PM
$RARE Ultragenyx Pharmaceutical (NASDAQ: RARE) is gaining attention among investors searching for high-growth biotechnology stocks. With a pipeline focused on rare genetic diseases and strong analyst price targets, the biotech stock could deliver more than 160% upside. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-invest-in-ultragenyx-pharmaceutical-rare/
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 5:44 AM
$RARE Current Stock Price: $22.07 Contracts to trade: $22.5 RARE Mar 20 2026 Call Entry: $1.48 Exit: $2.87 ROI: 93% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Masonsy
Masonsy Mar. 3 at 12:27 AM
$RARE going to resubmit UX111 BLA to FDA tomorrow or later this week. Will make sure all documents are attached and in good order. PRV expected. PDUFA date expected for late September- Early October.
0 · Reply
Estimize
Estimize Mar. 2 at 2:03 PM
Wall St is expecting -1.43 EPS for $RARE Q1 [Reporting 04/30 AMC] http://www.estimize.com/intro/rare?chart=historical&metric_name=eps&utm_c
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 25 at 7:16 PM
$RARE Share Price: $22.80 Contract Selected: Aug 21, 2026 $17.5 Calls Buy Zone: $6.71 – $8.29 Target Zone: $12.58 – $15.37 Potential Upside: 77% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 24 at 8:21 PM
$RARE shows building momentum on 1D as RSI climbs. While 1W remains neutral, 4H and 30M CCI indicate short-term strength. Despite legal headlines, technical signals suggest a shift toward a more constructive mid-term structure. @DailyAnalysis
0 · Reply
SaTwits
SaTwits Feb. 24 at 6:24 AM
$RARE getting them to print in Aug
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 23 at 8:48 PM
$RARE $CRSP $NTLA $BMRN $BBIO
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 23 at 8:29 PM
$RARE shows building momentum on 1D as RSI climbs. While 1W remains neutral, 4H and 30M CCI indicate short-term strength. Despite legal headlines, technical signals suggest a shift toward a more constructive mid-term structure. @DailyAnalysis
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 23 at 6:29 PM
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder $RARE $VTI $XBI https://stocktwits.com/news/equity/markets/rare-stock-edges-up-on-priority-review-for-gene-therapy-in-rare-metabolic-disorder/cZRtz9oR4yr
0 · Reply
notreload_ai
notreload_ai Feb. 23 at 4:07 PM
$RARE one-time gene therapy DTX401 just got FDA Priority Review for Glycogen Storage Disease Type Ia (GSDIa). Possible approval by August 23, 2026 – the first treatment that could fix the root cause instead of just managing symptoms. https://notreload.xyz/fda-priority-review-for-dtx401-gene-therapy-in-gsdia/
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 22 at 6:45 PM
$RARE shows building momentum on 1D as RSI climbs. While 1W remains neutral, 4H and 30M CCI indicate short-term strength. Despite legal headlines, technical signals suggest a shift toward a more constructive mid-term structure. @DailyAnalysis
0 · Reply
DailyAnalysis
DailyAnalysis Feb. 21 at 10:06 PM
$RARE is deeply oversold on 1D RSI following clinical updates. The 1W chart shows value, but wait for 4H STOCH to confirm a trend shift. Watch 30M CCI for signs of a relief rally. @DailyAnalysis
0 · Reply